Short Bowel Syndrome Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class, By Distribution Channel, By Region & Competition, 2021-2031F

The Global Short Bowel Syndrome Market is projected to expand from USD 854.02 Million in 2025 to USD 1262.37 Million by 2031, registering a CAGR of 6.73%. This market encompasses therapeutic biologics and pharmaceuticals, such as growth hormones and glucagon-like peptide-2 analogs, aimed at improving nutrient absorption and facilitating intestinal adaptation in patients who have experienced significant small bowel resection. The primary catalyst for this growth is the rising prevalence of serious gastrointestinal conditions, including mesenteric ischemia and Crohn's disease, which require surgical intervention and ongoing management. Furthermore, the market is being bolstered by the creation of targeted therapies designed to decrease reliance on parenteral nutrition, thereby offering enhanced quality of life and better clinical results.

According to data from the American Society for Parenteral and Enteral Nutrition in 2024, the diagnosed prevalence of intestinal failure associated with short bowel syndrome was estimated at 0.12 to 2.74 per 100,000 adults worldwide. Despite this demand, the market faces a major obstacle in the form of prohibitive costs linked to advanced pharmacological treatments and long-term therapies. This high financial burden results in significant reimbursement challenges and restricts patient access, particularly within developing healthcare infrastructures, which effectively constrains the widespread adoption of these novel medical solutions.

Market Driver

The commercialization and adoption of novel GLP-2 analog therapies is fundamentally transforming the Global Short Bowel Syndrome Market by lessening patient dependence on lifelong parenteral nutrition. These advanced biologics simulate natural gut hormones to encourage intestinal adaptation, which significantly lowers the frequency and volume of intravenous fluids needed for survival. The rapid uptake of these treatments highlights a critical clinical need for solutions that reduce complications related to chronic catheter use. This momentum is reflected in the success of major market players; for instance, Takeda's May 2024 'FY2023 Full Year Results' reported that sales for its leading therapy, Gattex/Revestive, hit $796 million for the fiscal year 2023, fueled by high adherence rates and broadened patient access.

Simultaneously, a robust clinical pipeline of next-generation therapeutics is driving the market forward by introducing long-acting formulations designed to remove the burden of daily injections. Pharmaceutical developers are focusing on once-weekly dosing regimens expected to enhance patient compliance and quality of life relative to current care standards. As evidence of this progress, Ironwood Pharmaceuticals announced in a February 2024 press release that their investigational drug apraglutide achieved a 25.5 percent relative decrease in weekly parenteral support volume. These innovations target a high-value niche; Ironwood estimated in 2024 that Short Bowel Syndrome with Intestinal Failure affects approximately 18,000 adults across Europe, Japan, and the U.S., presenting a concentrated opportunity for these emerging treatments.

Market Challenge

The exorbitant costs associated with advanced pharmacological treatments and long-term therapy act as a major barrier to the growth of the Global Short Bowel Syndrome Market. The high price tags for chronic parenteral nutrition and specialized biologics cause significant friction with payers, often leading to stringent reimbursement protocols and frequent claim denials. This financial toxicity compels healthcare providers to restrict the prescription of novel therapies to only the most refractory or severe cases, effectively stifling product uptake. Consequently, the market struggles to expand in regions with developing healthcare infrastructures where public funding is inadequate to support such premium, lifelong treatments.

This economic burden on insurers and patients directly correlates with limited market expansion. In 2024, the PAN Foundation reported that its financial assistance program for Short Bowel Syndrome provided an initial grant of $18,200 to eligible patients, underscoring the substantial out-of-pocket costs faced even by those with insurance. Such a high level of financial liability discourages patient adherence and restricts the commercial reach of innovative medical solutions, thereby capping revenue potential throughout the sector.

Market Trends

The expansion of home-based parenteral nutrition services is shifting long-term care priorities from clinical settings to residential environments, aiming to enhance patient quality of life and cut hospital-related costs. This trend decentralizes the management of chronic intestinal failure, enabling patients to maintain their daily routines while receiving necessary nutritional support. However, the sustainability of this model is threatened by supply chain instability and rising operational expenses. A white paper released by the National Home Infusion Association in August 2025 noted that the cost of preparing home parenteral nutrition formulations rose by a compounded 75.4 percent between 2016 and 2024, placing significant economic strain on providers trying to scale these essential services.

Concurrently, a strategic focus on pediatric label expansions is emerging as a key growth driver, with pharmaceutical companies broadening their clinical targets to include the underserved pediatric population. By obtaining regulatory approvals for children, manufacturers are establishing early intervention protocols designed to mitigate the long-term developmental effects of short bowel syndrome, differentiating their strategies from purely adult-focused approaches. This pivot toward younger demographics is delivering tangible financial gains; according to an October 2025 PharmaLive article, sales for Takeda's Gattex/Revestive increased by 22.6 percent to $966 million in fiscal year 2024, a growth trajectory explicitly attributed to demand from pediatric indication label expansions.

Key Market Players

• Dentsply Sirona Inc.
• Emmaus Life Sciences, Inc.
• Merck & Co., Inc.
• Novartis AG
• OPKO Health, Inc.
• OxThera AB
• Pfizer Inc.
• Swedish Orphan Biovitrum AB
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.

Report Scope

In this report, the Global Short Bowel Syndrome Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Short Bowel Syndrome Market, By Drug Class

• GLP-2
• Glutamine
• Growth Hormone

Short Bowel Syndrome Market, By Distribution Channel

• Hospital Pharmacies
• Online Sales
• Retail Pharmacies

Short Bowel Syndrome Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Short Bowel Syndrome Market.

Available Customizations:

Global Short Bowel Syndrome Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).